Brief: Nexgel New Strategic Partner, Sequence Lifescience, Leads Financing With $5.5 Million To Complete Acquisition Of Celularity Degenerative Disease Segment
21/04/2026 14:09
April 21 (Reuters) - Celularity Inc CELU.O: NEXGEL NEW STRATEGIC PARTNER, SEQUENCE LIFESCIENCE™, LEADS FINANCING WITH $5.5 MILLION TO COMPLETE ACQUISITION OF CELULARITY DEGENERATIVE DISEASE SEGMENT Source text: ID:nGNX36GYx9 Further company coverage: CELU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform